ReviewResearch (Washington, D.C.)2025
Metal Nanomaterials: A Strategy to Combat Drug-Resistant Bacterial Infections.
Review in Research (Washington, D.C.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Exploring the Antimicrobial Efficacy of Graphene Oxide: Key Mechanisms and Future Directions.Pharmaceutics · 2026Review
- Nanomaterial strategies for antibiotic-resistant infections: Mechanistic frameworks, rational design, and clinical translation.Materials today. Bio · 2026Review
- Zinc/Catechol Resin-Based Microsphere Coating for Durable Antibacterial Cotton Fabrics.Polymers · 2026Article
- Overcoming Methicillin-ResistantResearch (Washington, D.C.) · 2026Article
- Antimicrobial Nanozymes: Structure-Activity-Guided Design, Synergy, and Applications.Research (Washington, D.C.) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bacterial infections pose a major challenge today due to the rise of drug resistance in pathogenic bacteria, creating an urgent need for the development of nonantibiotic therapies. Metal nanomaterials are increasingly recognized as promising antibacterial agents due to their unique physical and chemical properties, which offer strong antibacterial capabilities and broad-spectrum activity against drug-resistant bacteria. Unlike traditional antibacterial therapies, metal nanomaterials rarely induce drug resistance because of their diverse antibacterial mechanisms, which destroy bacteria by directly damaging bacterial cells or generating oxidative stress. Metal nanomaterials have proven effective in treating various drug-resistant bacterial infections. This perspective highlights recent advances in metal nanomaterials for antimicrobial applications. Firstly, bacterial infections and the current dilemma are introduced. Next, recent progress in the antibacterial activity of metal nanomaterials against drug-resistant bacteria is summarized, along with the challenges in their antimicrobial applications. Finally, future prospects and remaining challenges associated with the use of metal nanomaterials to treat drug-resistant bacteria are discussed.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.